Ann: Actinogen presents latest Xanamem data at AD Conference, page-63

"Xanamem" is the marketing name of UE2343.
Its half life is 10 to 14 hours.
This was known before XanADu started.

See Webster et al article in British Journal of Pharmacology Vol 174 Issue 5.
Link to article is on on ACW website.

"UE2343 was identified as a potent, orally bioavailable, brain-penetrant 11β-HSD1 inhibitor and selected for clinical studies. No major safety issues occurred in human subjects. Plasma adrenocorticotropic hormone was elevated (a marker of systemic enzyme inhibition) at doses of 10 mg and above, but plasma cortisol levels were unchanged. Following multiple doses of UE2343, plasma levels were approximately dose proportional and the terminal t1/2 ranged from 10 to 14 h. The urinary tetrahydrocortisols/tetrahydrocortisone ratio was reduced at doses of 10 mg and above, indicating maximal 11β-HSD1 inhibition in the liver."

Source:
Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem&trade

by

Webster1,AndrewMcBride1, Margaret Binnie1, Karen Sooy1, Jonathan R Seckl1,RuthAndrew1, T David Pallin2,HazelJHunt3, Trevor R Perrior4,VincentSRuffles5, J William Ketelbey5,AlanBoyd6 and Brian R Walker1
1 Centre for Cardiovascular Science, University of Edinburgh, Queen’s Medical Research Institute, Edinburgh, UK,
2 Charles River Laboratories, Harlow, UK,
3 Corcept Therapeutics, Menlo Park, California, USA, 4 Domainex Limited, Cambridge, UK,
5 Actinogen Medical Ltd, Sydney, New South Wales Australia
6 Alan Boyd Consultants Ltd, Crewe,